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Clinical and experimental evidence indicates that the com-plement system, a powerful arm of the inflammatory 
response, is involved in stroke pathophysiology.1–3 Available 
evidence points to the lectin pathway (LP), one of the activation 
pathways of the complement system, as a major contributor 
to the progression of brain damage.4–6 In mice, targeting one 
of the LP initiator molecules, MBL (mannose-binding lectin), 
by pharmacological inhibition or genetic deletion reduces in-
jury.5,6 Notably in ischemic stroke patients, MBL deficiency is 
associated with smaller lesion and better outcome,5,7 highlight-
ing the relevance of MBL role in human brain ischemia.
Immunofluorescence studies in ischemic mice reveal that 
MBL is selectively deposited on the ischemic endothelium for 
several hours after injury and at least up to 48 hours and this 
deposition is reduced in mice treated with the MBL inhibitor 
Polyman 2.6 MBL deposition on the activated endothelium 
is consistent with its ability to recognize and bind epitopes 
exposed on the surface of damaged cells.8,9 The target mol-
ecules recognized by MBL on the activated endothelium and 
the mechanisms by which MBL deposited on the activated en-
dothelium contribute to brain injury are unknown. MBL and 
the LP not only drive the activation of the complement cas-
cade leading to inflammation, phagocytosis, and possibly lysis 
of target cells but also display a high degree of interaction 
with coagulation and kinin systems.10–14 Activation of these 
cascades results in increased inflammation, blood clotting, 
and vascular permeability, further contributing to brain dam-
age.12 Thus, MBL deposition on the ischemic endothelium 
seems to act as a hub of several crucial events contributing to 
ischemic injury.
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Objective—Circulating complement factors are activated by tissue damage and contribute to acute brain injury. The deposition 
of MBL (mannose-binding lectin), one of the initiators of the lectin complement pathway, on the cerebral endothelium 
activated by ischemia is a major pathogenic event leading to brain injury. The molecular mechanisms through which 
MBL influences outcome after ischemia are not understood yet.
Approach and Results—Here we show that MBL-deficient (MBL−/−) mice subjected to cerebral ischemia display better flow 
recovery and less plasma extravasation in the brain than wild-type mice, as assessed by in vivo 2-photon microscopy. This results 
in reduced vascular dysfunction as shown by the shift from a pro- to an anti-inflammatory vascular phenotype associated with 
MBL deficiency. We also show that platelets directly bind MBL and that platelets from MBL−/− mice have reduced inflammatory 
phenotype as indicated by reduced IL-1α (interleukin-1α) content, as early as 6 hours after ischemia. Cultured human brain 
endothelial cells subjected to oxygen-glucose deprivation and exposed to platelets from MBL−/− mice present less cell death and 
lower CXCL1 (chemokine [C-X-C motif] ligand 1) release (downstream to IL-1α) than those exposed to wild-type platelets. In 
turn, MBL deposition on ischemic vessels significantly decreases after ischemia in mice treated with IL-1 receptor antagonist 
compared with controls, indicating a reciprocal interplay between MBL and IL-1α facilitating endothelial damage.
Conclusions—We propose MBL as a hub of pathogenic vascular events. It acts as an early trigger of platelet IL-1α release, 
which in turn favors MBL deposition on ischemic vessels promoting an endothelial pro-inflammatory phenotype.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38:2678-
2690. DOI: 10.1161/ATVBAHA.118.311058.)
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Platelets are key elements of thromboinflammatory cas-
cades, and their role in inflammatory processes is increasingly 
recognized.15–17 A mutual complement-platelet activation pro-
cess exists in which both partners directly support each other 
in their functions.18 Platelets express complement proteins and 
regulatory molecules, suggesting their susceptibility to com-
plement activation,18 although a specific role for LP has never 
been proposed.
Overall, available evidence suggests a role of LP in vas-
cular inflammation and injury but a coherent picture of its 
effects in ischemic vessels cannot be drawn yet. By using in 
vivo, ex vivo, and in vitro approaches in wild-type (WT) and 
MBL genetically deficient mice and analyzing different time 
points post-injury, we have explored MBL actions on cere-
bral hemodynamics and inflammatory effects with the aim of 
understanding MBL-driven events after ischemic injury. We 
show here that MBL drives platelet inflammatory phenotype 
and release of IL-1α (interleukin-1α) early after ischemia. In 
turn, IL-1α acts as a trigger for MBL whose presence sub-
sequently sustains the vascular pro-inflammatory phenotype, 
contributing to brain injury after stroke.
Materials and Methods
All data and materials have been made publicly available at 
the Figshare repository and can be accessed at doi:10.6084/
m9.figshare.7007921.
Animals
Procedures involving animals and their care were conducted in con-
formity with institutional guidelines that are in compliance with 
national and international laws and policies. Male 9- to 11-week-
old C57Bl/6J mice with target mutation of MBL-A and MBL-C 
genes (MBL−/−, 26–28 g, purchased from Jackson Laboratories and 
colonized at Mario Negri Institute), IL-1αβ−/− and IL-1R1−/− mice,19 
and wild-type C57Bl/6J mice (WT, 25–28 g, used as the control 
strain as indicated in the strain datasheet for the mutated mice; visit 
https://www.jax.org/strain/006122) were used. The experiments on 
IL-1Ra (interleukin-1 receptor antagonist)-treated (100 mg/kg via 
subcutaneous injection) and IL-1 αβ−/− mice and respective WT 
controls were done under appropriate United Kingdom Home 
Office licenses and adhered to the Animals (Scientific Procedures) 
Act (1986). The protocols and details of this report are in accord-
ance with ARRIVE guidelines (Animal Research: Reporting In 
Vivo Experiments; http://www.nc3rs.org.uk/page.asp?id=1357; 
check list provided in the online-only Data Supplement). We used 
only male mice since estrogens affect the ischemic outcome in ex-
perimental models.20 The study of the hormonal contribution to the 
ischemic lesion was beyond this work’s purposes, for example, 
exploring the mechanisms of MBL-driven endothelial damage.
Surgery Protocols
Transient Middle Cerebral Artery Occlusion
Transient middle cerebral artery occlusion (tMCAo) was induced 
with a siliconized filament (7-0, Doccol Corporation) introduced into 
the right carotid artery and advanced to block the origin of middle 
cerebral artery (MCA) for 30 minutes, as described previously.6,21 
Surgery-associated mortality rate was 7%. See also online-only 
Data Supplement. Surgery and treatment protocols used for IL-1Ra-
treated and IL-1 αβ−/− mice and respective WT controls are described 
previously.22
Cranial Window for Two-Photon Imaging
Mice were isoflurane-anesthetized with rectal temperature main-
tained at 37°C and positioned on a stereotactic frame (KOPF, CA). 
A cranial window was opened at AP: −1 mm and L: −2.5 mm from 
bregma to expose vessels in the region fed by the MCA.23,24 After 
a midline scalp incision, the periostium was gently removed and a 
round cranial window (2.3 mm in diameter, wide enough to uncover 
the distal branches of the MCA) was performed. Mice were allowed 




Craniotomized mice were kept under gaseous anesthesia (1.5% iso-




, 30/70 %) during imaging. Images 
were acquired with a BX51WI microscope coupled to an FV300 
scanner head (Olympus Corporation, Tokyo, Japan), equipped with 
a multiphoton laser, Chamaleon ultra II (Coherent, Santa Clara). 
Vessels were labeled by intravenous injection of rhodamine-dextran 
(RhITC, Sigma Aldrich; 70 kDa, 2.5% in sterile water, 120 μL). 
Pial and penetrating arterioles were acquired over a volume sized 
800×600×200 μm. The acquisition volume was placed within the first 
300 μm below the dura mater, in an area which is susceptible to the 
ischemic injury induced by tMCAo.23 The penetrating arterioles that 
were analyzed had a portion parallel to the cortical surface before div-
ing perpendicularly, thus allowing blood flow speed quantification25 
as described below. Details of acquisition protocol can be found in 
online-only Data Supplement.
Image Processing for Vessel Diameter, Blood Flow 
Speed, and Extravasation Measurements
All the vessels with diameter <45 μm were included in the follow-
ing measurements obtained using Fiji software.26 Further details on 
image processing can be found in online-only Data Supplement.
Vessel Lumen Diameter
A maximum projection image over the stack containing a given ves-
sel was used to quantify labeled pixel length (=vessel lumen).
Blood Flow Speed
Blood flow speed was calculated as red blood cells (RBC) speed 
(mm/s) according to the line-scan method.25 A negative value for 
speed indicates inversion of the blood flow from the baseline. 
Absolute values were used to quantify the percent of baseline value 
used for the statistical analysis.
Extravasation
Extravasation was identified by parenchymal accumulation of the 
fluorescent marker (which cannot cross the intact blood-brain bar-
rier).24 A mean projection image was obtained over the stack con-
taining a given vessel. Extravasation was calculated as the ratio of 
intra- to extravascular pixel density. Scattered cells taking up the dye 
(possibly macrophages and astrocytes) were excluded from pixel 
Nonstandard Abbreviations and Acronyms
hBMEC human brain microvascular endothelial cells
ICAM-1 intracellular adhesion molecule-1
IL-1R1 interleukin-1 receptor





RBC red blood cell
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density calculation (Figure I in the online-only Data Supplement). All 
data are expressed as the-fold change from the pre-occlusion time.
Immunohistochemistry
Immunohistochemistry was done on 20 μm brain coronal cryosec-
tions using biotinylated anti-mouse ICAM-1 (intracellular adhesion 
molecule-1; 1 µg/mL; R&D Biosystems, No. 553251), rat anti-
mouse CD206 (10 µg/mL; Serotec, Kidlington, No. MCA2235, 
UK), anti-mouse thrombomodulin (1 µg/mL; R&D Biosystems, No. 
MAB3894), and rat anti-mouse CD31 (0.16 µg/mL; BD Pharmigen, 
No. 550274). A secondary biotinylated antibody against rat was used. 
Positive cells were stained by reaction with 3,3 diaminobenzidine-
tetrahydrochloride (Vector laboratories, CA). For negative control 
staining, the primary antibodies were omitted, and no staining was 
observed (Figure II in the online-only Data Supplement).
Slice Selection and Quantitative Analysis 
for Immunohistochemistry
Three brain coronal sections per mouse (+0.6, 0, and –0.6 mm from 
bregma27) were used for quantification of markers in striatum, rep-
resenting the core of the lesion and cortex, representing the perile-
sional area/penumbra region. On each slice, anatomically defined 
striatal and cortical regions of interest were marked out, indicating 
regions in the territory fed by the MCA.23 See also online-only Data 
Supplement and Figure III in the online-only Data Supplement. The 
immunostained areas for ICAM-1 and thrombomodulin, expressed as 
positive pixels/total assessed pixels (percentage area stained), number 
of CD206+ cells/mm2, or density of grid touchings28 for CD31 were 
measured using Fiji software and used for statistical analysis.29
Immunofluorescence
Immunofluorescence was done on 20-μm-thick coronal brain sections. 
After blockade with 2% normal donkey serum or BSA for 1 hour, 
sections were incubated in mixtures of rabbit anti-Iba1 (0.4 µg/mL; 
WAKO, No. PA5-48108), goat anti-IL-1α (2 µg/mL; RnDsystems, 
No. AF-400), rat anti-CD41 (5 µg/mL; BD Biosciences, No. 553847), 
rabbit anti-C3 (4 µg/mL; Santacruz, No. H-300 sc-20137), or rat anti-
MBL-C (1 µg/mL; Hycult, No. HM1038) primary antibodies fol-
lowed by appropriate Alexa 488- or Alexa 594-conjugated secondary 
antibodies raised in donkey or goat (4 µg/mL; Life Sciences). Blood 
vessels were visualized with biotinylated tomato lectin (Sigma, 10 
µg/mL) followed by incubation with streptavidin Alexa 350-conju-
gated (2 µg/mL; Life Sciences) or Griffonia Simplicifolia isolectin 
B4 Alexa 488-conjugated (10 µg/mL; Life Sciences). For negative 
control staining, the primary antibodies were omitted, and no stain-
ing was observed (Figure II in the online-only Data Supplement). 
Confocal microscopy was done using a sequential scanning mode to 
avoid bleed-through effects with an Olympus FV500 microscope.30 
Three-dimensional volumes were acquired over 7 to 10 µm stacks, 
with 0.23 µm step size.30 For the quantification of MBL-C staining, 
microphotographs were taken in the ischemic cortex (×40 magnifica-
tion, pixel size 0.45 μm) and processed by ImageJ. Briefly, a region of 
interest was delineated on the IB4 signal (blood vessels). The region of 
interest was then applied to the corresponding image with the MBL-C 
signal after appropriate normalization (the background noise was cor-
rected by subtracting the mean pixel density of unstained areas). The 
integrated density was calculated and used for statistical analysis. For 
the assessment of microglial IL-1α production, double immunofluo-
rescence (using rabbit-anti Iba1 and goat anti-IL-1α antibodies, see 
above) was performed. IL-1α-positive microglia were counted in the 
ipsilateral hemisphere (2 randomly selected fields of view taken from 
3-3 coronal brain sections in each mouse using fixed coordinates de-
fined according to bregma). For the immunofluorescence on plate-
lets, these cells were collected from WT ischemic mice at 6 hours 
after tMCAo as previously described.31 Platelets were then primed 
in Tyrode’s buffer containing 1 mmol/L CaCl
2
 and incubated for 30 
minutes at 37°C with 1/10 (v/v in Tyrode’s buffer) plasma pooled 
from 3 tMCAo 6-hour mice. Three microliter of the platelet suspen-
sion were spotted on a gelatinized glass to run immunofluorescence 
with rat anti-mouse MBL-A or MBL-C (both 1 µg/mL; Hycult, No. 
HM1035 and No. HM1038, respectively) followed by Alexa 546-con-
jugated secondary antibody raised in goat (4 µg/mL; Life Sciences) 
and FITC-conjugated phalloidin (7.5 U/mL; Life Sciences). Confocal 
microscopy was done with a sequential scanning mode with a Nikon 
A1 system (×100 magnification, pixel size 0.1 μm).
Western Blot Analysis
Blood samples were collected in 10 mmol/L ethylendiaminetetracetic 
acid and 0.125% polybrene (Sigma-Aldrich), and plasma was sepa-
rated and stored at −80°C. Plasma proteins (10 μg/sample) were elec-
trophoresed and transferred to polyvinylidene fluoride membranes. 
Rat anti-thrombomodulin monoclonal antibody (10 µg/mL; R&D, 
No. MAB3894) or rabbit anti-C3 polyclonal (2 µg/mL; Santa Cruz 
Biotechnology, No. H-300 sc-20137) followed by anti-rat or anti-
rabbit peroxidase-conjugated antibodies (respectively, 0.04 µg/mL or 
0.16 µg/mL; Santa Cruz Biotechnology). Quantifications were done 
using Quantity 1 Software (Bio-Rad), and results were standardized 
using the total protein loaded (Ponceau solution, Bio-Rad).
Cytokine Measurement
Platelets and blood cells were lysed in ice-cold buffer (50 mmol/L 





1% Triton X) containing protease inhibitors (Calbiochem) for 30 
minutes followed by centrifugation for 10 minutes at 15 000g. Mouse, 
IL-1α and CXCL1 (chemokine [C-X-C motif] ligand 1) were meas-
ured with DuoSet ELISA kits (R & D Systems) according to the 
manufacturer’s protocol. Protein concentrations were calculated with 
BCA assay (Pierce, Thermo-Fisher Scientific).
Platelet Activation Assay
Platelets were isolated from the right cardiac ventricle of anesthetized 
male C57BL/6 mice as previously described.31 The platelets were 
resuspended in Tyrode’s buffer and exposed to 10 μg/mL recombi-
nant MBL (R&D) with or without 1 mmol/L CaCl
2
 and incubated at 
37°C for 30 minutes. Platelets were labeled with CD62P-APC and 
CD42d-PE antibodies (both 0.5 µg/mL; eBioscience, No. 17-0626-82 
and No. 12-0421-82, respectively) for 5 minutes before flow cyto-
metric analysis using a BD FACSVerse instrument (BD Biosciences).
Human Brain Microvascular Endothelial 
Cells and Oxygen-Glucose Deprivation
Human brain microvascular endothelial cells (hBMECs; Innoprot) 
were cultured on fibronectin-coated (15 μg/mL) black 96-well 
μ-plates (ibidi cell in focus, Germany) in basal medium supple-
mented with fetal bovine serum, endothelial cell growth cocktail, and 
penicillin/streptomycin solution (Innoprot). In vitro ischemia was in-
duced by 5 hours oxygen-glucose deprivation (OGD) as previously 
described.32
To assess the role of platelets in vitro, platelets were gathered 
from WT and MBL−/− naive mice (n=8/10) as previously described31 
and pooled in separate vials for each genotype. After the OGD pe-
riod, hBMECs were incubated with normoglycemic modified me-
dium with or without WT or MBL−/− platelets (145×103 cells/well).
Cell Death Measurement
Forty-eight hours after OGD, hBMECs were incubated with propid-
ium iodide fluorescent dye (5 μg/mL; Sigma-Aldrich). Propidium io-





=617 nm; TECAN plate reader, Infinite M200, Switzerland). 
Cells were then fixed for 30 minutes at room temperature with 4% 
paraformaldehyde. Nuclei were stained with 4′-6-diamidino-2-phe-
nylindole (1 µg/mL; Invitrogen), and fluorescence was measured 




=458 nm). Cell death was 
expressed as propidium iodide over 4′-6-diamidino-2-phenylindole 
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Experimental Design, Blinding, 
and Exclusion Criteria
In each experiment, WT and MBL−/− mice were randomly allocated 
to surgery groups taking care to distribute them equally across exper-
imental days to avoid systematic errors. All subsequent evaluations 
were made by blinded investigators. Animals with no deficits dur-
ing the occlusion period or with subarachnoid hemorrhage detected 
after brain removal were excluded from the study (3% of total tMCAo 
animals).
Statistical Analysis
Comparisons among groups were done by ANOVA and post hoc test as 
indicated in each figure legend. The parametric or nonparametric test 
was selected after a Kolmogorov-Smirnov test for normality to assess 
whether groups met normal distribution. The constancy of variances 
was checked by Bartlett test. Welch’s corrected 1-way ANOVA fol-
lowed by Games-Howell test was used for normally distributed data 
with unequal variances (Figures 2A, 3A, 4C, 5A, 5D′, 5F, and 5G). 
Group size was defined as the following formula: n=2σ2f(α,β)/Δ2 
(SD in groups=σ, type 1 error α=0.05, type II error β=0.2, percentage 
difference between groups Δ=30). For each measure, the SD between 
groups was calculated on the basis of previous experiments with the 
same output parameters (eg, for stained area quantification σ=19, 
yielding n=6.34).
Statistical analysis was done using standard software packages 
GraphPad Prism (GraphPad Software Inc, San Diego, CA; version 
6.0); P values <0.05 were considered significant.
Please see the Major Resources Table in online-only Data 
Supplement for further details.
Results
MBL Deficiency Ameliorates Impaired 
Hemodynamic Responses After Ischemia
In vivo 2-photon microscopy (2-PM) was used to measure 
brain hemodynamics in WT or MBL−/− ischemic mice. 
Two-PM in vivo imaging sessions were done longitudinally at 
selected time points (Figure 1A): before (pre), 1 hour (post-1 
hour), and 24 hours (post-24 hours) after the onset of ischemia, 
induced by tMCAo. Two-PM imaging was performed over the 
cortical region fed by the MCA, for example, where blood 
flow is reduced and cell death occurs.23 The acquired volumes 
(Figure 1B) were used to measure RBC speed, extravasation, 
and vessel lumen diameter at the selected times. As expected, 
both WT and MBL−/− mice had significant drops in RBC speed 
1 hour after ischemia. However, at post-24 hours, MBL−/− 
mice showed significantly better blood flow recovery than WT 
mice, the latter showing a further reduction in RBC speed at 
this time point (Figure 1C). WT and MBL−/− mouse vessels 
had comparable extravasation of the fluorescent dye at 1 hour 
post-ischemia, but MBL−/− mice had significantly less extrav-
asation than WT mice at post-24 hours, indicating an earlier 
improvement of blood-brain barrier leakage (Figure 1C). WT 
mouse vessels indeed had a progressive increase in extravasa-
tion over time up to post-24 hours. Data on extravasation refer 
to a cortical region near to the brain surface as 2-PM imaging 
was limited to the first 300 µm below the dura mater; thus, 
deeper parenchymal leakage from brain capillaries was not 
measured. Conversely, the contribution of subarchnoid space 
bleeding cannot be excluded.
Both WT and MBL−/− mice showed no significant changes 
in vessel lumen diameter after ischemia compared to the pre 
time point—likely due to the effect of isoflurane which was 
used as anesthetic33—and no difference between genotypes 
(Figure 1C) thus showing that the reported changes were not 
due to changes in diameter. Moreover, WT and MBL−/− had 
no differences in RBC speed, vessel lumen diameter, and 
flux rate before ischemia (pre; Table I in the online-only Data 
Supplement), and previous studies demonstrated no genotype 
differences in cerebrovascular anatomy.34 We can therefore 
exclude that the hemodynamic differences observed between 
the 2 genotypes depend on different local vasodilatation or on 
strain differences in blood flow or vessel anatomy.
WT and MBL−/− sham mice had no differences in vessel 
diameter and blood flow speed at any of the time points ana-
lyzed (Figure IV in the online-only Data Supplement).
MBL Deficiency Induces a Shift From a 
Pro- to an Anti-Inflammatory Vascular 
Phenotype in Ischemic Brain Areas
Since MBL deficiency ameliorates impaired hemodynamic 
responses after ischemia, suggesting an attenuation of vas-
cular inflammatory responses, we assessed measures of vas-
cular inflammation and function.
Assessment of C3 fragments, that result from C3 enzy-
matic cleavage, and of its deposition on the ischemic tissue 
are index of complement activation. Twenty-four hours after 
tMCAo, ischemic MBL−/− mice had lower C3b plasma lev-
els than ischemic WT mice, indicating an attenuated comple-
ment systemic activation (Figure 2A and complete Western 
blot experiment shown in Figure V in the online-only Data 
Supplement), consistent with MBL role as initiator molecule 
of LP of complement activation. In addition, locally, immuno-
fluorescent analysis of C3 protein showed that MBL−/− mice 
(Figure 2B′) had less C3 deposited on the ischemic cortical 
area than WT (Figure 2B). C3 appeared located close to ves-
sels pertinent to the ischemic area.
ICAM-1, a protein expressed by activated endothelial 
cells and involved in the recruitment of inflammatory cells to 
the injured brain,35,36 was undetectable in both strains in naive 
mice, but it increased over time after tMCAo in striatum and 
cortex (respectively, P=0.0002 and P=0.0164; Figure 3A and 
3B). Notably, ischemic MBL−/− mice had lower ICAM-1 ex-
pression in striatum than ischemic WT mice 24 hours after 
tMCAo (Figure 3A). No differences between ischemic WT 
and MBL−/− mice were found in cortex, where the staining in-
tensity was weak (Figure 3B).
CD206-positive perivascular macrophages, which repre-
sent a resident macrophage subset involved in permeability 
control and blood-brain barrier integrity,37 were on the contrary 
increased as a consequence of MBL deletion. CD206-positive 
cells increased with time after ischemia in striatum and cortex 
(P=0.0003 and P=0.0022, respectively; Figure 3C and 3D). 
MBL−/− mice had a higher number of CD206-positive cells 
than WT mice in striatum and cortex 24 hours after tMCAo 
(Figure 3C and 3D).
To further explore the consequences of MBL deficiency 
on vascular inflammation, we then focused on thrombo-
modulin, an anti-inflammatory protein expressed on the 
surface of endothelial cells which also acts as a negative reg-
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thrombomodulin expression was significantly reduced in the 
striatum and in cortex of both strains (surgery effect, striatum: 
P=0.0002; cortex: P<0.0001; Figure 4A and 4B). However, 
24 hours after ischemia, this anti-inflammatory protein was 
significantly higher in the cortex of MBL−/− than in WT mice 
(Figure 4B). Thrombomodulin cleavage product (thrombo-
modulin-lectin domain, TMD1) can be shed and found in 
blood as a circulating protein. Twenty-four hours after is-
chemia, MBL−/− mice had significantly higher levels of cir-
culating TMD1 compared with WT mice (Figure 4C and 
complete Western blot experiment shown in Figure V in the 
online-only Data Supplement).
Vessel density, measured by CD31 staining, did not differ 
between the 2 groups (for tMCAo mice at 24 hours, striatum: 
Figure 1. MBL (mannose-binding lectin) deficiency ameliorates impaired hemodynamic responses after ischemia as assessed by in vivo 2-photon micros-
copy. A, Wild type (WT) or MBL−/− mice underwent craniotomy and in vivo imaging before (pre), 1 h (post-1 h), and 24 h (post-24 h) after ischemic onset. B, 
Representative images of the acquired volume at each time point for WT and MBL−/− mice from a ventral perspective. Vessels are labeled by rhodamine-
dextran injected systemically, pseudocolored in red and blue to depict arterioles and venules, respectively, at pre. Asterisks indicate penetrating capillaries. 
Rhodamine-dextran is shown also in white to compare each time point. Both strains showed a significant drop in red blood cells (RBC) speed at post-1 h, 
but MBL−/− had better flow recovery than WT at post-24 h (C). In both strains extravasation appeared at post-1 h, but MBL−/− showed less extravasation 
than WT at post-24 h (C). Both strains had no significant changes in vessel lumen diameter after ischemia compared with pre, with no differences between 
genotypes (C). Individual vessel changes (% of pre) are plotted (n=14–25 vessels from 4 mice per strain). Data are expressed as aligned dot plot with bars at 
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912.1±68.5 for WT versus 945.1±175.9 for MBL−/−; cortex 
869.0±84.6 for WT versus 985.6±251.0 for MBL−/−, den-
sity expressed as grid touchings per mm2; Figure VI in the 
online-only Data Supplement), indicating that the reported 
differences in the vascular expression of the above-mentioned 
molecules were not due to different vessel density in the 2 
genotypes.
At 24 hours after injury, the ischemic lesion did not differ 
between the 2 genotypes (19.76±5.10 versus 20.54±6.99 mm3, 
mean±SD; Figure VII in the online-only Data Supplement).
MBL Deficiency Selectively Lowers 
IL-1α Expression in Platelets
IL-1 is a major pro-inflammatory cytokine produced by both 
microglia and peripheral immune cells that drives ICAM-1 
expression on cerebral microvessels.31 Since hematopoi-
etic IL-1 contributes to brain injury and vascular inflamma-
tion after cerebral ischemia39 and platelets are an important 
source of IL-1α31, we measured IL-1α levels in different 
cell types 6 hours after tMCAo. Platelets from MBL−/− mice 
had lower IL-1α expression levels than those from WT mice 
(Figure 5A). In contrast, blood cells pelleted from whole 
blood or microglia in the brain did not show any difference 
in IL-1α expression in the 2 genotypes (Figure 5B). Since 
platelet aggregation is associated with a greater brain injury,40 
we investigated whether MBL−/− mice presented differences 
in the number of platelet aggregates in cerebral microves-
sels compared with WT. We found no differences in platelet 
aggregates between the genotypes (Figure VIII in the online-
only Data Supplement). Importantly, we found that platelets 
are capable of binding MBL on their surface, as evidenced 
by immunoreactivity of platelets for both MBL murine iso-
forms after incubation with plasma from 6-hour tMCAo 
mice (Figure 5C). To test whether this interaction could drive 
platelet activation, we isolated platelets from naive WT mice 
and incubated them with recombinant MBL (10 µg/mL) for 





 alone induced a slight (not significant) increase in 
platelet activation, while MBL significantly increased platelet 
activation in the presence of CaCl
2
. In contrast, MBL alone 
(ie, in the absence of CaCl
2
) did not induce platelet activation 
(Figure 5D and 5D′).
Platelets From MBL−/− Mice Attenuate OGD-
Induced CXCL1 Release and Death Compared 
to Platelets From WT Mice in hBMEC
Next, we checked whether MBL would induce platelets to 
alter their inflammatory profile after hypoxia/ischemia. Since 
platelets drive vascular inflammation via IL-1α31, we inves-
tigated whether MBL deficiency contributed to the weaker 
endothelial injury after ischemia through platelet-mediated 
responses. Cultured hBMECs monolayers were exposed to 5 
hours OGD or left under normoxic conditions. hBMECs were 
then incubated 48 hours with vehicle medium or platelets from 
WT or MBL−/− mice (145×103 cells/well; Figure 5E). Cultured 
medium from OGD-hBMECs exposed to MBL−/− platelets 
had lower levels of CXCL1 than OGD-hBMEC exposed to 
WT platelets (Figure 5F). hBMEC cell death was significantly 
greater after the OGD insult compared with normoxic con-
dition, irrespective of treatment (Figure 5G). However, OGD 
Figure 2. MBL (mannose-binding lectin) deficiency attenuates complement activation. Western blot analysis of C3b fragments in plasma of wild-type (WT) 
and MBL−/− naive or ischemic mice 24 h after transient middle cerebral artery occlusion (tMCAo) showed that ischemic MBL−/− mice have less circulating C3b 
fragments after tMCAo (A; the complete gel with all samples is shown in Figure V in the online-only Data Supplement). Data are expressed as scatter dot plot 
with line at mean±SD¸ n=6; Welch corrected 1-way ANOVA followed by Games-Howell test, *P<0.05. Immunostaining in the ischemic cortex shows that C3 
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hBMECs exposed to MBL−/− platelets had significantly less 
cell death than those exposed to WT platelets (Figure 5G).
Blockade of IL-1 Signaling Decreases 
MBL Deposition on Ischemic Vessels 
24 Hours After Ischemia
Mice deficient for IL-1αβ or those treated with IL-1Ra show 
markedly reduced brain injury after cerebral ischemia.41–43 
To investigate the interplay between MBL and IL-1-related 
pathways, we measured MBL deposition in the ischemic 
area of WT mice treated with the competitive IL-1R1 (IL-1 
receptor 1) antagonist, IL-1Ra (100 mg/kg, subcutaneously), 
or with vehicle, in IL-1αβ knock out (IL-1αβ−/−) and in IL-1 
receptor 1 knock out (IL-1R1−/−) mice, 24 hours after tMCAo, 
a time point when deposition is maximal.6 Mice treated with 
IL-1Ra showed a significant 59%, IL-1αβ−/− mice a 47% and 
IL-1R1−/− mice a 48% decrease of MBL deposition on the is-
chemic vessels compared with controls (Figure 6). Thus, be-
yond its direct actions on brain microvessels and neurons,41 
IL-1 released from platelets seems also to augment vascular 
injury and subsequent brain damage by facilitating vascular 
MBL deposition after cerebral ischemia.
Figure 3. MBL (mannose-binding lectin) deficiency reduces ICAM-1 (intracellular adhesion molecule-1) and raises CD206 expression in ischemic brain 
areas. Representative images of ICAM-1 staining in striatum (A) or cortex (B) of wild-type (WT) and MBL−/− mice 24 h after transient middle cerebral artery 
occlusion (tMCAo) (bar=50 μm). ICAM-1 was detectable only in ischemic mice in both strains. Twenty-four hours after tMCAo MBL−/−, mice had lower ex-
pression of ICAM-1 than WT mice in striatum (A). Representative images of CD206 staining in striatum (C) or cortex (D) of WT and MBL−/− mice 24 h after 
tMCAo (bar=20 μm). At this time point, MBL−/− ischemic mice had a higher number of CD206+ cells in striatum (C) and cortex (D) than WT mice. Data are 
expressed as scatter dot plot with line at mean±SD, n=5–6; Welch corrected 1-way ANOVA followed by Games-Howell test for ICAM-1, *P<0.05; 2-way 





 http://ahajournals.org by on Septem
ber 22, 2020
Orsini et al  Mannose-Binding Lectin and Vascular Damage  2685
Discussion
This study shows that MBL drives vascular responses after 
cerebral ischemia through platelet-derived IL-1α, thus pro-
posing a previously unexplored mechanism of detrimental 
complement actions after stroke. In particular, MBL seems to 
promote an inflammatory phenotype in platelets early after is-
chemia. Platelet IL-1α, in turn, favor MBL deposition on the 
ischemic vessels, sustaining the vascular inflammatory phe-
notype that ultimately drives the ischemic lesion expansion. 
Thus, MBL- and IL-1-mediated actions interact to establish 
vascular inflammatory responses and brain injury after cere-
bral ischemia.
Both MBL and IL-1 deficiency are associated with smaller 
brain injury and better functional outcome after cerebral is-
chemia.5,6,39,41 Here we report better hemodynamics and an 
attenuated endothelial inflammatory phenotype in MBL−/− mice 
24 hours after ischemia. At this time point, WT and MBL−/− 
have similar lesion volume, ruling out the possibility that the 
effects of MBL deletion described here at 24 hours are sec-
ondary to the reduced injury. As previously published by us and 
others,5,6 MBL−/− mice show smaller lesion volume at 48 hours 
after insult, thus suggesting that MBL activates secondary 
mechanisms which contribute to lesion expansion. The similar 
ischemic lesion that we observed at 24 hours in our model does 
not contradict previous findings reporting a significant protec-
tion at 24 hours in MBL−/− mice when using a stronger ischemic 
insult, for example, 90′ tMCAo and showing a wider lesion 
size at this time point (lesion volume ≈50 mm3).34
Available evidence supports that MBL deficiency is as-
sociated with better reperfusion after ischemia.34 Here we 
Figure 4. MBL (mannose-binding lectin) deficiency increases thrombomodulin expression and its shedded circulating lectin domain (TMD1). Representa-
tive images of thrombomodulin staining in striatum (A) and cortex (B) of wild-type (WT) and MBL−/− mice 24 h after transient middle cerebral artery occlu-
sion (tMCAo; bar = 50 μm). At this time point, MBL−/− ischemic mice had higher thrombomodulin expression in cortex than WT ischemic mice (B). Data 
are expressed as scatter dot plot with line at mean±SD, n=5–6; 2-way ANOVA followed by Sidak’s post hoc test (surgery effect P=0.0002 for striatum and 
P<0.0001 for cortex, not shown); *P<0.05, **P<0.01. Quantitative analysis of thrombomodulin immunoblot indicated that 24 h after tMCAo, MBL−/− mice had 
higher levels of thrombomodulin lectin-domain (TMD1, 25 kDa) in plasma than WT mice (C; the complete gel with all samples is shown in Figure V in the 
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show by in vivo 2-PM that MBL−/− mice have better vascular 
function than WT mice 24 hours after ischemia, with faster 
blood flow and lower extravasation values. The attenuation of 
vascular dysfunction is not apparent early after the insult (1 
hour), implying that the observed effects are not due to genetic 
changes in the vasculature, but rather to MBL activation of 
secondary mechanisms affecting vascular function. In vivo 
2-PM, high resolution allows to study individual vessels over 
time. In MBL−/− ischemic mice, we observed better function of 
small vessels with a diameter smaller than 45 µm, which are 
Figure 5. MBL (mannose-binding lectin) deficiency selectively lowers IL-1α (interleukin-1α) expression in platelets which induce less CXCL1 (chemokine 
[C-X-C motif] ligand 1) release and less cell death in vitro when exposed to human brain microvascular endothelial cells (hBMECs) subjected to oxygen-
glucose deprivation (OGD.) Six hours after transient middle cerebral artery occlusion (tMCAo), IL-1α content was significantly reduced in platelets (A) but not 
in other blood cells or in microglia (B) from MBL−/− mice compared with wild-type (WT) mice. Data are expressed as scatter dot plot with line at mean±SD, 
n=6; Welch corrected 1-way ANOVA followed by Games-Howell test, **P<0.01. Platelets extracted from ischemic WT mice and incubated with murine plasma 
were clearly positive for MBL-A and MBL-C (C; arrowheads, the right panel shows the negative control for the immunostaining, bars=20 μm). Platelets from 
naive WT mice showed significant activation (increased CD62P levels) when incubated for 30 min with MBL in the presence of CaCl2 (representative cyto-
metric density plots in D and quantification in D′). Data are expressed as scatter dot plot with line at mean±SD, n=5–8, Welch corrected 1-way ANOVA fol-
lowed by Games-Howell test, ***P<0.001 vs control. Platelets obtained from MBL−/− mice when incubated with hBMECs subjected to OGD (E) induced lower 
CXCL1 release (F) and less cell death (G) than those obtained from WT mice. Data are expressed as scatter dot plot with line at mean±SD, n=6, Welch cor-
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believed to be the most susceptible to secondary blood clot-
ting. Events of no-reflow are indeed typical of small vessels36 
and can have a great effect on brain viability.44 Well-known 
secondary pathogenic mechanisms include fibrin and platelet 
deposits,31,45,46 local vasoconstriction caused by pericytes,47 
and deposition of intravascular clusters of immune cells dur-
ing their recruitment,24 all events promoting secondary clots 
and driving focal no-reflow.36
MBL deficiency–related amelioration of hemodynamic 
responses after ischemia improved vascular inflammatory 
response, showing an overall shift from a pro-inflammatory 
to an anti-inflammatory phenotype, for example, decreased 
C3b (complement activation48) and endothelial ICAM-1 (an 
adhesion molecule which facilitates leukocyte endothelial 
transmigration).
Interestingly, CD206-positive macrophages increased in 
the ischemic area of MBL−/− mice, indicating that MBL de-
letion favors a protective and anti-inflammatory environment. 
These macrophages are located at the interface between ves-
sels and brain parenchyma as they patrol the albuminal space of 
the cerebral vasculature. They act by limiting vessel leakage37 
and inflammation, promoting prohealing processes after brain 
damage,49 similarly to other M2 polarized myeloid cells.50 
MBL deficiency was also associated with increased endo-
thelial expression of the anticoagulant and anti-inflammatory 
protein thrombomodulin and with increased circulating levels 
of its fragment TMD1.51 Thrombomodulin anchors to the lu-
minal side of the vascular endothelial cell membrane, exerting 
physiological control of blood flow.52 Among its several an-
ti-inflammatory actions, thrombomodulin prevents excessive 
blood clotting by inhibiting the conversion of fibrinogen into 
fibrin by thrombin.10,38 The observed increase in endothelial-
bound thrombomodulin 24 hours after ischemia therefore 
suggests an antithrombotic profile of the endothelium in 
MBL−/− mice. The N-terminus end of thrombomodulin may 
be cleaved into short 25 kDa fragments containing a lectin-
like domain (TMD1), which may directly bind HMGB1 (high 
mobility group box 1) and prevent the activation of RAGE on 
endothelial cells.38,53 TMD1 also modulate the expression of 
ICAM-1 and VCAM-1 (vascular cell adhesion molecule 1)51. 
In addition, and relevant for our study, TMD1 may negatively 
regulate the complement system.54 In our study, TMD1 plas-
matic concentrations in MBL−/− ischemic mice significantly 
increased compared with WT mice 24 hours after injury. This 
Figure 6. IL-1 (interleukin-1) receptor 1 (IL-1R) inhibition decreases MBL (mannose-binding lectin) deposition on ischemic vessels 24 h after ischemia. Rep-
resentative images of MBL-C (red) and vessels (IB4, green) from wild-type (WT; A), IL-1R antagonist-treated (B), IL-1αβ−/− (C), or IL-1R1−/− (D) mice (bars=20 
µm). The fluorescence intensity of MBL-C staining (integrated density) was decreased in IL-1R antagonist-treated, IL-1αβ−/− and IL-1R1−/− compared with WT 
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is consistent with an anti-inflammatory role of TMD1 after 
ischemia and suggests that MBL can downregulate TMD1 
production, resulting in an enhanced inflammatory vascular 
phenotype. The TMD1 increase in MBL−/− ischemic mice 
may explain the observed tendency in C3b level drop after 
ischemia in these mice. This hypothesis is in line with the re-
ported ability of TMD1 to negative complement regulation,54 
although we acknowledge that other unknown mechanisms 
may be involved in this effect.
The improvement in hemodynamics and the changes in 
vascular inflammatory response in MBL−/− ischemic mice 
were evident 24 hours after injury, with no change at earlier 
times (1 hour and 6 hours, respectively). To further explore 
events occurring early after ischemia and possibly explain 
later events, 6 hours after ischemic onset, we measured in-
flammatory cytokines in different cellular compartments. We 
found that 6 hours after ischemia platelets (but not other blood 
cells or microglia) had a dramatically lower IL-1α content 
compared with WT mice. IL-1α released by platelets has a 
critical role in inflammation-mediated injury in the brain.31 
In fact, it induces the endothelial expression of ICAM-1, 
VCAM-1, and CXCL1, besides enhancing neutrophil trans-
endothelial migration, all well-known mechanisms of brain 
damage after injury.31,55–57
We show here for the first time that murine platelets bind 
MBL, and high MBL levels may facilitate platelet activa-
tion in a calcium-dependent manner, implying a direct in-
volvement of platelets in MBL-driven pathological effects. 
We thus tested whether MBL deficiency contributed to the 
reduced endothelial injury after ischemia through plate-
let-mediated responses. Consistent with our hypothesis, 
hBMEC subjected to OGD and incubated with platelets 
from MBL−/− mice showed significantly reduced release of 
CXCL1, a chemokine whose release is driven by platelet 
IL-1α,31 than platelets from WT. In line with the pro-inflam-
matory function of platelets in ischemic injury, our overall 
data define for the first time a role of MBL in inducing 
IL-1α release from platelets. Our data indicate that this is an 
early consequence of ischemia (6 hours), impacting on ves-
sel viability over the first 24 hours and possibly leading to 
neuronal injury by 48 hours.6 Counteracting IL-1α release 
by MBL deletion results in preserved microvessel function 
24 hours after ischemia.
Further supporting the link between MBL and IL-1α, ge-
netic deletion of IL-1 or its receptor and IL-1R antagonism 
reduced MBL deposition 24 hours after ischemia, a time when 
high MBL deposition is expected.6 These mice were also pro-
tected from the ischemic injury, having smaller lesion size and 
decreased vascular permeability,43 further supporting the key 
role of this pathway in driving vascular damage.
Conclusions
In this study, we show that MBL deficiency is associated with 
decreased cerebrovascular dysfunctions and endothelial pro-
inflammatory phenotype after brain ischemia, compared with 
controls, and propose a central role for platelet IL-1α in MBL-
mediated endothelial damage.
The detrimental effects of MBL depend at least in part 
on its interaction with platelets. As a working hypothesis 
(Figure 7), we propose that early after ischemia (6 hours), cir-
culating MBL drives platelet activation. Active platelets re-
lease IL-1α that on binding to its receptor (IL-1R1) causes 
vascular inflammation, facilitating vascular injury. Later on, 
24 hours after injury, damaged endothelial cells induce MBL 
deposition triggering complement activation (cleaved C3) and 
favoring a pro-inflammatory activation of the endothelium 
(ICAM-1) to the detriment of protective functions (CD206 and 
thrombomodulin and TMD1). Therefore, MBL contributes to 
Figure 7. MBL (mannose-binding lectin) and IL-1α (Interleukin-1α) interplay on the ischemic endothelium and its consequences. Early after ischemia (6 h), 
circulating MBL drives platelet activation by a direct action on platelets. Actived platelets release IL-1α, which on binding to its receptor (IL-1R) contributes to 
endothelial damage.31 Damaged endothelial cells drive MBL deposition,6 which results in complement activation, increase of ICAM-1 (intracellular adhesion 
molecule-1) expression on vessels, favoring focal no-reflow,36 decrease of thrombomodulin (TM) expression on the endothelium and of its circulating shedded 
domain (TMD1), all effects indicative of vascular inflammation, and decrease of CD206-positive perivascular macrophages in the brain, a population involved 
in blood-brain barrier (BBB) structural maintenance.37 All these events contribute to reduction of blood flow speed and increase of BBB leakage observed 
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the final ischemic injury by activating detrimental cascades on 
the ischemic endothelium within 24 hours, which may kick 
off subsequent inflammatory pathways.
We propose MBL as a hub of pathogenic vascular events. 
The interaction with IL-1α is indeed one of the possible path-
ways by which MBL exerts its detrimental role after ischemia. 
However, we acknowledge that these effects may be linked 
to other molecular interactions, or to direct endothelial dam-
age induced by MBL deposition as reported in few in vitro 
studies using renal peritubular epithelial cells,58 or colorectal 
carcinomal cells.59
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Highlights
• Mannose-binding lectin directly binds platelets inducing IL-1α (interleukin-1α) release.
• IL-1α favors mannose-binding lectin vascular deposition.
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